WS
ARCT icon

Wedbush Securities’s Arcturus Therapeutics ARCT Stock Holding History

Wedbush Securities’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,943
Closed -$220K – 1107
2021
Q4 		$220K Sell
5,943
-11,682
-66% -$476K 0.01% 1020
2021
Q3 		$842K Sell
17,625
-6
-0% -$269 0.04% 405
2021
Q2 		$597K Sell
17,631
-8,432
-32% -$285K 0.03% 562
2021
Q1 		$1.08M Buy
+26,063
New +$1.55M 0.06% 310

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedbush Securities's ARCT Position: Q1 2022 in Review

Wedbush Securities sold out of Arcturus Therapeutics (ARCT) in Q1 2022, closing a stake of 5,943 shares — an estimated $220K sold.

Wedbush Securities first reported a position in ARCT in Q1 2021 and held it in 4 quarters. The position peaked at $1.08M in Q1 2021. 130 funds tracked by Wall St. Rank hold ARCT as of Q1 2022.

  • Wedbush Securities reported no remaining Arcturus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Wedbush Securities sold 5,943 Arcturus Therapeutics shares in Q1 2022, an estimated $220K.
  • Wedbush Securities first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 4 quarters.
  • Wedbush Securities's Arcturus Therapeutics position peaked at $1.08M in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2022.

Based on Wedbush Securities's 13F filing for Q1 2022, filed 19 Apr 2022.